The present invention provides a synergistic composition of bioactive fraction essentially constituting iridoid glucosides, acetyl barlerin and shanzhiside methyl ester isolated from a plant source Barleria prionitis linn along with a process for the isolation of the bioactive fraction, the present invention also relates to a method of treating mammals and humans for hepatotoxicity, stress and immuno-deficiency with the synergistic bioactive composition.

Council of Scientific and Industrial Research

Synergistic composition of bioactive fraction isolated from barleria prionitis linn and a method of treatment for hepatotoxicity, immuno-deficiency and fatigue and a process thereof

The use of a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor for the treatment of fatigue syndromes, including chronic fatigue syndrome, post-infectious fatigue syndromes, fatigue syndromes associated with human immunodeficiency virus (HIV) infection or with preeclampsia. The acetyl cholinesterase is preferably one that acts substantially selectively at nicotinic receptor sites, and which has selectivity for acetyl cholinesterase as opposed to butyryl cholinesterase. Compounds of the invention include galanthamine and galanthamine derivatives.

Treatment of fatigue syndrome

A supplementary therapeutic agent for the treatment of immunodeficiency syndrome with reduced NK (natural killer) activity and an immunopotentiator preparation containing it are provided.A supplementary therapeutic agent for immunopotentiation which comprises L-cysteine, L-cystine, or L-glutamine, or salts thereof and is used in combination with an immunopotentiator such as lentinan, OK-432, sizofiran or the like, and an immunopotentiator preparation containing the agent. This combination of agents is useful as a supplementary therapeutic agent for the treatment of an immunodeficiency, such as low NK activity syndrome, chronic fatigue syndrome, acquired immunodeficiency syndrome, or congenital immunodeficiency syndromes.

Ajinomoto Co., Inc.

Supplementary therpeutic agents for the treatment of immunodeficiency syndrome

The present invention is directed to a psychostimulant containing pharmaceutical composition comprising an enteric coating and showing a sustained release of said psychostimulant in vivo. The invention is further directed to the use of said pharmaceutical composition in the treatment of the Attention Deficit Hyperactivity Disorder (ADHD) and comorbidities, narcolepsy, fatigue and/or cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome or oncological diseases. Additionally, the present invention provides a method for the manufacture of said pharmaceutical composition.

primary immunodeficiency diseases/vermoeidheid

Synergistic composition of bioactive fraction isolated from barleria prionitis linn and a method of treatment for hepatotoxicity, immuno-deficiency and fatigue and a process thereof

Treatment of fatigue syndrome

Supplementary therpeutic agents for the treatment of immunodeficiency syndrome

Psychostimulant containing pharmaceutical composition

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap